FDA approves Amgen's Prolia for new use
(Reuters) - Amgen Inc, the world's largest biotechnology company, said U.S. health regulators approved its Prolia injection for a new use as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.
People suffering from osteoporosis experience severe weakening and thinning of bones.
Prolia currently has U.S. approval to treat postmenopausal women with osteoporosis at high risk for fracture. The drug brought in sales of $120 million to Amgen between April and June, up 36 percent sequentially.
According to the National Osteoporosis Foundation, two million men in the U.S. have osteoporosis and another 12 million are at risk, Amgen said in a statement.
(Reporting by Zeba Siddiqui in Bangalore)
- Tweet this
- Share this
- Digg this
- UPDATE 1-Don't mess with nuclear Russia, Putin says
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |
- Don't mess with nuclear Russia, Putin says
- Exclusive - Over 100 Russian soldiers killed in single Ukraine battle - Russian rights activists
- Scotland's pro-independence campaign gains on final TV debate - poll